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Background: Alopecia areata is the hair loss usually reversible, in sharply defined areas. The treatment of alopecia
using growth factors shows interesting activity in promoting hair growth. In this concept, VEGF (vascular
endothelial growth factor) is a marker of angiogenesis, stimulating hair growth by facilitating the supply of nutrients
to the hair follicle, increasing follicular diameter. The aim of this study was the evaluation of a topical gel enriched
with VEGF liposomes on the hair growth stimulation and its toxicological aspects.
Methods: Mesocricetus auratus were randomly divided into three groups. Control group was treated with
AristoflexW gel, 1% group with the same gel but added 1% VEGF and 3% group with 3% VEGF. Biochemical,
hematological and histological analyses were done.
Results: At the end of the experiment (15th day of VEGF treatment) efficacy was determined macroscopically by
hair density dermatoscopy analysis, and microscopically by hair diameter analysis. They both demonstrated that hair
of the VEGF group increased faster and thicker than control. On the other hand, biochemical and hematological
results had shown that VEGF was not 100% inert.
Conclusions: VEGF increased hair follicle area, but more studies are necessary to confirm its toxicity.
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Alopecia is a generic term to define hair loss. There are
different kinds of alopecia, triggered by immunological,
metabolic or unknown causes [1].
The pathologic aspect of hair loss is a social problem.
Many treatments have been proposed for hair loss treat-
ment throughout history, dating back to Egyptian papyri
of 4000 a. C. Many dermatologic treatments and cos-
metic products are being developed to improve hair
density and to stop, or at least to decline, the loss [2].* Correspondence: profferfonseca@gmail.com
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reproduction in any medium, provided the orIt is very important to identify correctly which kind of
alopecia will be treated to achieve a good clinical result
[3]. Currently, the treatment is drawn based on clinical
type of alopecia that affects the patient [4].
Two classes of active cosmetics were recently released.
The first class was defined as “Growth Factors”. These
proteins are produced through the process of genetic en-
gineering, introducing the gene encoding within the
DNA of E. coli, allowing large-scale production of these
peptides. One of the great advantages of this process is
that the recombinant proteins acquired in the process
are 100% homologous to human, reducing the risk of al-
lergic reactions to the product [5].
The product passes through a purification process gen-
erating the pure peptide. This peptide is then nanoencap-
sulated, where it is encased in liposomes, forming aLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Hair density assessed by FotoFinder dermoscopeW MedicamW 500. (A) Control group. (B) 1% VEGF. (C) 3% VEGF.
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uct, protecting against endogenous proteases and increas-
ing the penetration through the skin [5].
The treatment of alopecia using growth factors shows
interesting activity in promoting hair growth. In this
concept, VEGF (vascular endothelial growth factor) is a
marker of angiogenesis, stimulating hair growth by facili-
tating the supply of nutrients to the hair follicle, increas-
ing follicular diameter [5].
It was demonstrated that the expression of VEGF in
human alopecia follicles significantly decreased compar-
ing to the normal follicles [6]. It was observed that Min-
oxidil, one of the pharmaceutical treatments approved
for the therapy of Alopecia, could promote hair growth
through upregulating the expression of VEGF in hair
dermal papilla cells [7].
Considering the explanation above, the aim of this
study was the quantitative evaluation of a topical gel
enriched with VEGF liposomes on the hair growth
stimulation and its toxicological aspects regarding
changes in biochemical and hematological parameters as
well as the histopathological analysis.
Methods
Animals
This study was approved by the Committee of Ethics and
Animal Experimentation of FMABC (protocol number
001/2010). The care and handing of the animals were in ac-
cordance with the National Institute of Health guidelines.
Treatments
18 hamsters (Mesocricetus auratus) were randomly di-
vided into three groups, each one with 6 animals. ControlTable 1 Hair density obtained by dermatoscopy analysis
(analyzed area: 0.65 cm2; density unit: 1/cm2)
Group Average density (1/ cm2) s.d. Min. Max. p*
Control 387.93 59.66 312.6 493.1 0.999
1% VEGF 388.57 64.45 305.7 506.9 0.9525
3% VEGF 379.28 49.6 207.4 445.5 0.002
*p<0.05, N = 6. Non-parametric Kruskal-Wallis test, with multiple comparisons
made by the Dunn’s test for the three-groups comparison (control x 1% x 3%).group was treated with AristoflexW gel, 1% group with the
same gel but added 1% VEGF and 3% group with 3%
VEGF. All animals had their backs shaved with a regular
razor before treatment. An area of 2 cm2 was topically
treated with 650 μL of formulation twice daily for 15 days.
On the 13th day animals were shaved once more and
photos of their backs were taken with the FotoFinder
dermoscopeW MedicamW 500. The procedure was re-
peated on the 14th and 15th days. All images collected
were analyzed by DermoscopeW 3.8 software.
At the end of the experiment (15th day), animals were
anesthetized with a mixture of xylazine (10 mg/ kg/ ip)
and ketamine (100 mg/ kg/ ip). Blood was collected from
the aorta artery for hematological and biochemical ana-
lyses. After animals sacrifice, the skins were collected
and fixed with 10% phosphate buffered formalin.
Hematological and biochemical analyses
Hematological analysis was conducted in the ABX Pen-
tra 60 - HoribaW cell counter. Microscope slides were
also performed for qualitative analysis of the blood cells.
Aspartate aminotransferase (AST), alanine amino-
transferase (ALT), gamma glutamyl transferase (GGT)
and alkaline phosphatase were assessed using BiotécnicaW
reagents kit.
All analytical procedures were performed following the
good practice in clinical laboratory analysis.
Histological analysis
Graded dehydration, paraffinization, and embedding
were carried out on the fixed specimens. Paraffin sec-
tions (5 μm) were cut and processed for hematoxylin-
eosin (HE) staining for image analysis. The imagesTable 2 Hair density obtained by ImageJW software
analysis (analyzed area: 0.65 cm2; density unit: 1/cm2)
Color Group Average Area s.d. Min. Max. p**
Control 559.21 543.36 54 6980 0.996
HE 1% VEGF 613.8 686.86 52 17253 0.001
3% VEGF 707.77 914.52 48 22116 0.001
**p<0.05, N = 6. Non-parametric Kruskal-Wallis test, with multiple comparisons
made by the Dunn’s test for the three-groups comparison (control x 1% x 3%).
Figure 2 Cross and longitudinal sections of animal treated with 1% of VEGF.
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scope. Epidermal, dermal and subcutaneous thickness
was measured in digital images of HE-stained sections
using the Micrometrics Plus software. The thickness of
hair follicles was measured in HE-stained sections at
the level of the largest diameter of hair bulbs with
clearly visible dermal papilla (50 hair follicles for each
time point). Hair diameter was quantified by using the
ImageJW software.
Statistical analysis
Statistical analysis was performed by using the SPSS 17.0
software. All variables were analyzed descriptively.
Quantitative values were indicated by median, minimumFigure 3 Cross and longitudinal sections of animal treated with 3% o
Figure 4 Cross and longitudinal sections of control group.and maximum values. For the three-group comparison,
the non-parametric Kruskal-Wallis test was used, with
multiple comparisons made by the Dunn’s test. A level
of p < 0.05 was considered statistically significant.
Results
Dermoscopy images and capillary density
FotoFinder dermoscopeW MedicamW 500 and Dermos-
copeW 3.8 software were used to analyze the hair density
of the three groups: control, 1% VEGF and 3% of VEGF
after 15 days of treatment. The Figure 1 shows hair
density assessed by FotoFinder dermoscopeW MedicamW
500. The Table 1 shows analyzed area: 0.65 cm2; density
unit: 1/cm2.f VEGF.
Table 3 Biochemical analysis
Group Biochemical parameter Average (U/L) s.d. p
Control GGT 17.6 10.64 0.2453
1% VEGF GGT 3 0
3% VEGF GGT 6 7.07
Control AST 91.5 18.59 0.2834
1% VEGF AST 130.83 160.06
3% VEGF AST 70.7 30.22
Control ALT 194.7 84.57 0.5195
1% VEGF ALT 270 342.69
3% VEGF ALT 139.2 38.45
Control Alkaline phosphatase 51 16.87 0.9439
1% VEGF Alkaline phosphatase 77.5 86.07
3% VEGF Alkaline phosphatase 96.3 84.32
GGT, gamma-glutamyl transferase; AST, aspartate amino transferase; ALT, ala-
nine amino transferase. Non-parametric Kruskal-Wallis test, with multiple com-
parisons made by the Dunn’s test for the three-groups comparison (control x
1% x 3%). *A level of p < 0.05 was considered statistically significant.
Table 4 Hematological analysis
Variable Group n Average s.d. Min. Max. p*
WBC (103/mm3) Control 4 4.2 1.13 3.1 5.7 0.3834
1% 6 3.2 0.93 2.1 4.9
3% 6 3.4 0.86 2 4.5
RBC (106/mm3) Control 4 8.94 0.36 8.63 9.4 0.0217
1% 6 8.12 0.72 6.69 8.59
3% 6 8.57 0.32 8.23 9.14
Hb (g/dL) Control 4 16 0.88 15.4 17.3 0.1649
1% 6 15.3 0.66 14 15.8
3% 6 15.4 0.6 14.8 16.5
Ht (%) Control 4 47.6 2.01 45.2 49.7 0.1253
1% 6 43.4 3.94 35.5 45.6
3% 6 45.8 2.1 44 49.5
MCV (L/μm3) Control 4 53 0.96 52 54 0.9311
1% 6 53.5 0.55 53 54
3% 6 53.3 0.82 52 54
MCH (L/pg) Control 4 17.7 0.69 16.8 18 0.0201
1% 6 18.9 1.03 18 20.9
3% 6 17.9 0.18 17.7 18.2
Plt (103/mm3) Control 4 527 150 353 712 0.5584
1% 6 451 114.4 321 603
3% 6 482 67.6 402 536
Lin (%) Control 4 70.5 4.85 63.4 74.3 0.0615
1% 6 77.4 3.12 72.8 81.7
3% 6 70.3 9.33 62.4 81.5
Mon (%) Control 4 0.2 0.05 0.1 0.2 0.5601
1% 6 0.2 0.1 0 0.2
3% 6 1.05 0.6 0 1.5
Eos (%) Control 4 1.2 0.5 0.5 1.6 0.018
1% 6 0.3 0.4 0 1.1
3% 6 1.18 1.04 0.4 3.2
Bas (%) Control 4 4.5 1.9 2.1 7 0.6479
1% 6 5.6 1.8 3.1 7.6
3% 6 4.03 2.39 1.3 8
WBC, Leucocytes; RBC, Erythrocytes; Hb, Haemoglobin; Ht, Haematocrit; MCV,
Mean corpuscular volume; MCH, Mean corpuscular haemoglobin; Plt, Platelets;
Lin, Lymphocytes; Mon, Monocytes; Eos, Eosinophils; Bas, Basophils. Non-
parametric Kruskal-Wallis test, with multiple comparisons made by the Dunn’s
test. *A level of p < 0.05 was considered statistically significant.
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Photos were taken under a digital microscope and ana-
lyzed by ImageJW, measuring the area of each hair follicle
in order to compare the area of the hair follicle of the con-
trol group, 1% VEGF and 3% VEGF (Table 2, Figures 2, 3,
and 4).
Biochemical and hematological results (Tables 3 and 4).
Discussion
Our previous results have shown that a liposomal li-
quid gel formulation containing insulin-like growth
factor-1 (IGF-1) was efficacious in promoting hair
growth and density, without evidence of adverse effects
such as hepatoxicity [8]. This present study aimed to
verify the safety and efficacy of another growth factor –
VEGF. Mesocricetus auratus was selected as experi-
mental animal in both studies because growth factors
would be readily absorbed reaching systemic circulation
after its topical application. Thus, this could be a suit-
able animal model to study efficacy and safety of IGF-1
and VEGF [9].
The use of animal models has many advantages
since the follicle are in their natural physiological
environment and undergo normal cyclic activity. An-
other popular model is the black mouse C57BL/6.
Unfortunately, mice have the significant drawback of
patchy growth once the second wave of hair growth
has been completed [10]. Furthermore, FotoFinder
dermoscope MedicamW 500 needs a larger area to
analyze the hair density.
Our results show that as higher the concentration of
VEGF present in the gel sample, bigger is the hair follicle
area. Yano et al. [11] identified VEGF as a major mediatorof hair follicle growth and cycling and provided the first
direct evidence that improving follicle vascularization pro-
moted hair growth and increased hair follicle and hair size
in mice. It is known that VEGF is a growth factor that
stimulates vasculogenesis and angiogenesis, stimulating
hair growth by facilitating the supply of nutrients to the
hair follicle, providing even an increase in the base of the
follicle diameter [5,12,13].
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that VEGF is not 100% inert. Data obtained and repre-
sented in the Table 3 have indicated that the use of
VEGF enhanced AST and ALT levels in the 1% VEGF
group. Alkaline phosphatase values were high in both
1% and 3% VEGF groups. Despite all results were not
significant, they should be continuously analyzed.
VEGF-treated animals showed lower red blood cells
and mean corpuscular hemoglobin values than control
animals (Table 4). No significant differences were ob-
served when other blood parameters were analyzed, ex-
cept to eosinophils. VEGF treatment diminished the
number of eosinophils.
The treatment of alopecia using growth factors shows
interesting activity in promoting hair growth. On the
other hand, more toxicological studies are necessary to
confirm their safety.
Conclusion
VEGF increased hair follicle area, but more studies are
necessary to confirm its toxicity. As far as we know,
this is the first reference in literature that associates
hematological and hepatic effects with VEGF used to
promote hair growth.
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